Alabama NewsCenter — UAB Callahan Eye Hospital offering new gene therapy treatment for an inherited retinal disease

By Leah Glenn

The University of Alabama at Birmingham Callahan Eye Hospital has been named one of the newest sites for Spark Therapeutics’ Luxturna, the first gene therapy treatment approved by the Food and Drug Administration for a genetic disease.

It is a prescription gene therapy for patients with inherited retinal disease due to mutations in both copies of the RPE65 gene, which can be confirmed only through genetic testing. Patients must have viable retinal cells as determined by the treating physicians.

The AlabamaWx Weather Blog gladly brings you an excerpt of this article through a partnership with the Alabama NewsCenter. You can see the complete post featuring all the associated images, videos, and links by clicking HERE.

Category: ALL POSTS, Partner News Stories